TICKERNERD
Menu
AUPHAUPHHealthcare · Biotechnology

AUPH Stock Forecast: Aurinia Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$17
+1.53% on the day

The 7 Wall Street analysts covering Aurinia Pharmaceuticals, Inc. hold a median 12-month price target of $17 — +2.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 13 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.2B
Ticker Nerd rank
93 / 100
Median analyst target
$17
Analysts covering
7
Revenue$83.2M+18.9% y/y
Operating income$46.3M
Net income$37.4M
Free cash flow$52.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.7%
1M
+1.2%
YTD
+4.1%
1Y
+47.9%
From 52W high
−10.8%
From 52W low
+47.9%
$11
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AUPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aurinia Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
97
Volatility
96
Issuance
92
Growth
82
Momentum
74
Revisions
52
Size
34
Accruals
22

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

The Ticker Nerd Read

The model sees top-decile value while the Street's lone analyst holds.

As of October 9, 2026, our factor model ranks Aurinia 93.7 of 100. Value is the strongest driver at 99.1 of 100, and Quality runs nearly as high at 96.6. Investment and Accruals is the drag, at 21.9, with its earnings-quality measure the weakest piece.

That reading sits against a thin Street. One analyst covers the stock and rates it a Hold, with a median target of $17 against a last close of $16.65 on October 9, 2026. The Estimate Revisions factor is middling at 54.1 because analysts have trimmed their earnings forecasts over the past 90 days.

The earnings-quality flag points to the December 2025 quarter, when net income of $210.8 million dwarfed the $31 million to $37 million of the surrounding quarters. Reported profit has run ahead of cash: trailing net income is $314 million while cash from operations is $175 million. The trailing price-to-earnings ratio sits at 7.4 while the forward multiple is 15.8.

The Value factor at 99.1 says the shares cost little relative to the profits and assets the business carries, by the model's measure. In August 2026 Aurinia settled its voclosporin patent litigation with Teva; the agreement keeps potential US generic competition away until December 2036. Whether earnings start arriving as cash, and how the aritinercept pipeline develops, would move the reading.

As of 10 Oct 2026
Wall Street

AUPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AUPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18$20$22Jan 26Apr 26Jul 26Oct 26AUPHHigh $21Median $17Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $16Median $17High $21

The green dot is the last close — the median target sits +2.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsSector Perform$15 → $16
3 Dec 2025Leerink PartnersDowngradeMarket Perform—
3 Dec 2025Leerink PartnersDowngradeMarket Perform$15 → $16
7 Nov 2025JefferiesUpgradeBuy—
5 Nov 2025RBC CapitalDowngradeSector Perform—
1 Aug 2025RBC CapitalMaintainsOutperform—
30 July 2025HC Wainwright & Co.AssumesBuy$17
16 Sept 2024Cantor FitzgeraldReiteratesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.ReiteratesBuy—
23 Feb 2024Cantor FitzgeraldMaintainsOverweight—
22 Feb 2024HC Wainwright & Co.MaintainsBuy—
16 Feb 2024RBC CapitalMaintainsOutperform—
22 Sept 2023HC Wainwright & Co.ReiteratesBuy—
7 Aug 2023HC Wainwright & Co.MaintainsBuy$14 → $15
7 Aug 2023HC Wainwright& Co.MaintainsBuy—
6 July 2023Cantor FitzgeraldReiteratesOverweight—
3 May 2023HC Wainwright & Co.ReiteratesBuy—
23 Feb 2023RBC CapitalReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AUPH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AUPH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Aurinia Pharmaceuticals, Inc. returned +47.9% against +17.5% for the S&P 500, dividends included.

AUPH vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140150160Jan 26Apr 26Jul 26Oct 26AUPHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AUPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.7%
Analysts raising
1
Analysts cutting
2
Fundamentals

Aurinia Pharmaceuticals, Inc. (AUPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.2×

Cheaper than 63% of US stocks

Price / sales
7.0×

Cheaper than 18% of US stocks

Price / book
3.5×

Cheaper than 27% of US stocks

EV / EBITDA
10.1×

Cheaper than 37% of US stocks

Growth & margins
Revenue growth (YoY)
18.9%

Higher than 68% of US stocks

Earnings growth (YoY)
73.9%

Higher than 80% of US stocks

Gross margin
92.1%

Higher than 97% of US stocks

Operating margin
55.7%

Higher than 98% of US stocks

Net margin
100.8%

Higher than 99% of US stocks

Returns & dividend
Return on equity
66.1%

Higher than 94% of US stocks

Return on assets
15.5%

Higher than 97% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aurinia Pharmaceuticals, Inc. (AUPH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aurinia Pharmaceuticals, Inc. has a market value of $2.2B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $311.5M. The latest quarter grew 18.9% year on year.

  • Net income over the same four quarters: $314.1M, a 100.8% net margin.

  • Diluted earnings per share, trailing twelve months: $2.29.

  • Free cash flow in the twelve months to 30 June 2026: $175.1M.

  • Aurinia Pharmaceuticals, Inc. spent $83.6M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 132.9M.

  • Trailing P/E: 7.2×; forward P/E: 15.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Aurinia Pharmaceuticals, Inc. employs 128 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

AUPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AUPHAurinia Pharmaceuticals, Inc.$2.2B
93
CLDXCelldex Therapeutics, Inc.$2.2B
27
HRMYHarmony Biosciences Holdings, Inc.$2.1B
88
IRONDisc Medicine, Inc.$2.1B
33
NVAXNovavax, Inc.$2.1B
61
NRIXNurix Therapeutics, Inc.$2.2B
93
PHVSPharvaris NV$2.1B
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aurinia Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AUPH news & analysis

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Zacks Investment Research · 20 Aug 2026positive

Aurinia Pharmaceuticals settled its voclosporin patent litigation with Teva. The settlement delays potential generic competition in the United States until December 2036, and the company's stock rose following the news.

Why it matters — AUPH watchers would care because the settlement extends patent protection for voclosporin, reducing near-term generic competition risk for a key product.

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Benzinga · 20 Aug 2026positive

Aurinia Pharmaceuticals has entered into a settlement agreement with Teva Pharmaceutical Industries to resolve a patent dispute related to its kidney disease drug. Aurinia's shares rose in Thursday's premarket trading following the announcement.

Why it matters — The settlement removes patent litigation uncertainty for Aurinia's kidney disease drug, which could affect its competitive position and market outlook.

Aurinia Settles Patent Litigation with Teva

Business Wire · 19 Aug 2026neutral

Aurinia Pharmaceuticals announced it has settled patent litigation with Teva, according to a Business Wire release from Edmonton, Alberta. The settlement resolves the patent dispute between the two companies.

Why it matters — Resolving the patent litigation removes legal uncertainty around Aurinia's patent position that AUPH watchers had been monitoring.

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Seeking Alpha · 12 Aug 2026neutral

Aurinia Pharmaceuticals is advancing its pipeline, running the phase 4 PRESERVE trial in lupus nephritis testing combinations containing its drug Lupkynis, and developing aritinercept across four potential indications. However, Lupkynis could face potential challenges to its market exclusivity in the near future, and the company provides little clarity on timelines for further aritinercept updates.

Why it matters — AUPH watchers would care because this update addresses both the company's pipeline progress and potential risks to the market position of its key drug Lupkynis.

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Zacks Investment Research · 6 Aug 2026positive

Aurinia Pharmaceuticals reported Q2 earnings of $0.28 per share, surpassing the Zacks Consensus Estimate of $0.19 per share and up from $0.16 per share a year ago.

Why it matters — The results indicate Aurinia's quarterly earnings came in well above analyst expectations and improved year over year.

FAQ

Frequently asked questions about AUPH stock

What is the AUPH stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Aurinia Pharmaceuticals, Inc. have a median 12-month price target of $17, with estimates ranging from $16 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AUPH stock a buy right now?

Of the 7 analysts covering Aurinia Pharmaceuticals, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aurinia Pharmaceuticals, Inc. 93 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AUPH?

As at 13 Oct 2026, Aurinia Pharmaceuticals, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will AUPH stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +2.3% from the last close, and Ticker Nerd's factor model ranks Aurinia Pharmaceuticals, Inc. 93 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AUPH stock forecast for 2030?

No analyst covering Aurinia Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AUPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $21 over the next 12 months.

How has AUPH stock performed over the past year?

Aurinia Pharmaceuticals, Inc. returned +47.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aurinia Pharmaceuticals, Inc. do?

Aurinia Pharmaceuticals, based in Edmonton, Canada, develops and sells LUPKYNIS, an oral treatment for adults with active lupus nephritis, a serious kidney complication of lupus. The company serves patients and doctors mainly in the United States and Japan and employs about 128 people.

What is the latest news on AUPH?

The most recent item we track (Zacks Investment Research, 20 Aug 2026): "Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises". Aurinia Pharmaceuticals settled its voclosporin patent litigation with Teva. The settlement delays potential generic competition in the United States until December 2036, and the company's stock rose following the news.

Company

About Aurinia Pharmaceuticals, Inc.

Aurinia Pharmaceuticals, based in Edmonton, Canada, develops and sells LUPKYNIS, an oral treatment for adults with active lupus nephritis, a serious kidney complication of lupus. The company serves patients and doctors mainly in the United States and Japan and employs about 128 people. It is also advancing aritinercept, a pipeline drug aimed at autoimmune conditions.

CEO Mr. Kevin C. Tang · 128 employees · Canada · https://www.auriniapharma.com